We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABIOMED, Inc. recently announced preliminary results for third-quarter fiscal 2020.
Revenues are anticipated at $221.6 million, suggesting a 10% year-over-year rise but below the Zacks Consensus Estimate of $227.1 million.
The company is scheduled to release full financial results on Feb 6, before market open.
Investors Not Happy
ABIOMED’s fiscal third-quarter preliminary results have dampened investors’ spirits. Share price of this Zacks Rank #3 (Hold) company plummeted 11% to close at $168.10 since the release.
Also, shares of ABIOMED have plunged 48.4%, against the industry's 16.5% growth, over the past year. The current level also lags the S&P 500’s rally of 28.3%.
View Slashed
ABIOMED slashed its fiscal 2020 revenue guidance.
The company expects revenues within $846-$877 million, indicating an increase of 10-14%, year over year. This is compared to the earlier projected range of $885-$925 million, calling for a 15-20% rise year over year. The Zacks Consensus Estimate for the same stands at $886.24 million, much above the guided range.
In the fiscal third quarter, ABIOMED’s international growth was 24%, while U.S. patient usage grew 16% year over year. U.S. revenues grew 8% year over year to $185.6 million.
Internationally, revenues totaled $36.0 million, up 29% year over year buoyed by strength in Germany and Japan.
Per management, ABIOMED was negatively impacted by two conference presentations, which were said to be based on misleading analyses.
Summing Up
ABIOMED is confident to have gained from its flagship Impella product line in the third quarter. Revenues from Germany and Japan have driven sales in the quarter, while U.S. patient use also rose year over year. However, a slashed guidance for fiscal 2020 is concerning.
DexCom’s fourth-quarter earnings growth rate is projected at 31.5%.
HealthEquity’s long-term earnings growth rate is 25%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View
ABIOMED, Inc. recently announced preliminary results for third-quarter fiscal 2020.
Revenues are anticipated at $221.6 million, suggesting a 10% year-over-year rise but below the Zacks Consensus Estimate of $227.1 million.
The company is scheduled to release full financial results on Feb 6, before market open.
Investors Not Happy
ABIOMED’s fiscal third-quarter preliminary results have dampened investors’ spirits. Share price of this Zacks Rank #3 (Hold) company plummeted 11% to close at $168.10 since the release.
Also, shares of ABIOMED have plunged 48.4%, against the industry's 16.5% growth, over the past year. The current level also lags the S&P 500’s rally of 28.3%.
View Slashed
ABIOMED slashed its fiscal 2020 revenue guidance.
The company expects revenues within $846-$877 million, indicating an increase of 10-14%, year over year. This is compared to the earlier projected range of $885-$925 million, calling for a 15-20% rise year over year. The Zacks Consensus Estimate for the same stands at $886.24 million, much above the guided range.
ABIOMED, Inc. Price and Consensus
ABIOMED, Inc. price-consensus-chart | ABIOMED, Inc. Quote
Quarter Highlights
In the fiscal third quarter, ABIOMED’s international growth was 24%, while U.S. patient usage grew 16% year over year. U.S. revenues grew 8% year over year to $185.6 million.
Internationally, revenues totaled $36.0 million, up 29% year over year buoyed by strength in Germany and Japan.
Per management, ABIOMED was negatively impacted by two conference presentations, which were said to be based on misleading analyses.
Summing Up
ABIOMED is confident to have gained from its flagship Impella product line in the third quarter. Revenues from Germany and Japan have driven sales in the quarter, while U.S. patient use also rose year over year. However, a slashed guidance for fiscal 2020 is concerning.
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space are Cerner Corporation , DexCom (DXCM - Free Report) and HealthEquity (HQY - Free Report) . While HealthEquity sports a Zacks Rank #1 (Strong Buy), Cerner and DexCom carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cerner’s long-term earnings growth rate is 13.6%.
DexCom’s fourth-quarter earnings growth rate is projected at 31.5%.
HealthEquity’s long-term earnings growth rate is 25%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>